8-K Announcements
6Material company update
Jun 3, 2026·SEC
Material company update
May 18, 2026·SEC
Material company update
Apr 27, 2026·SEC
Medtronic plc(MDT)Earnings, Financials & Key Ratios
MDT•NYSE
22.0× P/E·Price updated Jun 19, 2026
AboutMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.Show more
- Revenue$33.54B+3.6%
- EBITDA$8.82B+13.2%
- Net Income$4.66B+26.8%
- EPS (Diluted)3.61+30.8%
- Gross Margin65.32%
- EBITDA Margin26.29%+9.2%
- Operating Margin17.76%+11.7%
- Net Margin13.9%+22.4%
- ROE9.45%+31.2%
MDT Key Insights
Medtronic plc (MDT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Dividend Aristocrat: 44 years of consecutive increases
- ✓FCF machine: 15.5% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 3.5%
- ✓Share count reduced 3.0% through buybacks
- ✓Healthy 5Y average net margin of 13.0%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when MDT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDT Price & Volume
Medtronic plc (MDT) stock price & volume — 10-year historical chart
Loading chart...
MDT Growth Metrics
Medtronic plc (MDT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.17%
5 Years3.01%
3 Years1.91%
TTM6.88%
Profit CAGR
10 Years5.71%
5 Years-0.54%
3 Years-2.56%
TTM8.31%
EPS CAGR
10 Years4.12%
5 Years0.39%
3 Years-1.08%
TTM9.12%
Return on Capital
10 Years6.65%
5 Years6.65%
3 Years6.92%
Last Year7.54%
MDT Recent Earnings
Medtronic plc (MDT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 11/12 qtrs (92%)
Q3 2026Latest
Jun 3, 2026Metric
Actual
Est
EPS
$1.55+0.6%
$1.54
Rev
$9.8B+1.9%
$9.6B
Q1 2026
Feb 17, 2026Metric
Actual
Est
EPS
$1.36+1.5%
$1.34
Rev
$9.0B+1.2%
$8.9B
Q4 2025
Nov 18, 2025Metric
Actual
Est
EPS
$1.36+3.8%
$1.31
Rev
$9.0B+1.1%
$8.9B
Q3 2025
Aug 19, 2025Metric
Actual
Est
EPS
$1.26+2.4%
$1.23
Rev
$8.6B+2.4%
$8.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 3, 2026 | $1.55vs $1.54+0.6% | $9.8Bvs $9.6B+1.9% |
| Q1 2026 | Feb 17, 2026 | $1.36vs $1.34+1.5% | $9.0Bvs $8.9B+1.2% |
| Q4 2025 | Nov 18, 2025 | $1.36vs $1.31+3.8% | $9.0Bvs $8.9B+1.1% |
| Q3 2025 | Aug 19, 2025 | $1.26vs $1.23+2.4% | $8.6Bvs $8.4B+2.4% |
Based on last 12 quarters of dataView full earnings history →
MDT Peer Comparison
Medtronic plc (MDT) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 EW | 50.37B | 87.36 | 47.74 | 11.55% | 17.64% | 10.35% | 0.07 | |
 SYK | 117.88B | 307.80 | 36.64 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ZBH | 17.22B | 87.97 | 24.78 | 7.2% | 9.05% | 5.77% | 0.59 | |
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 |
Compare MDT vs Peers
Medtronic plc (MDT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDT Income Statement
Medtronic plc (MDT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 29.71B | 29.95B | 30.56B | 28.91B | 30.12B | 31.69B | 31.23B | 32.36B | 33.54B | 35.48B |
Revenue Growth % | 3.04% | 0.82% | 2.02% | -5.38% | 4.16% | 5.21% | -1.45% | 3.64% | 3.62% | 6.88% |
Cost of Goods Sold | 9.29B | 9.07B | 9.15B | 9.42B | 10.48B | 10.14B | 10.72B | 11.22B | 11.63B | 13.5B |
COGS % of Revenue | 31.28% | 30.27% | 29.96% | 32.59% | 34.81% | 32.02% | 34.33% | 34.66% | 34.68% | - |
Gross Profit | 20.42B▲ 0% | 20.89B▲ 2.3% | 21.4B▲ 2.5% | 19.49B▼ 8.9% | 19.63B▲ 0.7% | 21.54B▲ 9.7% | 20.51B▼ 4.8% | 21.15B▲ 3.1% | 21.91B▲ 3.6% | 21.98B▲ 0% |
Gross Margin % | 68.72% | 69.73% | 70.04% | 67.41% | 65.19% | 67.98% | 65.67% | 65.34% | 65.32% | 61.95% |
Gross Profit Growth % | 3.68% | 2.3% | 2.47% | -8.94% | 0.74% | 9.71% | -4.8% | 3.12% | 3.58% | - |
Operating Expenses | 15.03B | 14.25B | 15.13B | 14.7B | 15.15B | 15.79B | 15.02B | 16B | 15.95B | 15.64B |
OpEx % of Revenue | 50.6% | 47.56% | 49.53% | 50.84% | 50.3% | 49.83% | 48.11% | 49.45% | 47.56% | - |
Selling, General & Admin | 10.02B | 10.24B | 10.42B | 10.11B | 10.15B | 10.29B | 10.41B | 10.74B | 10.85B | 11.45B |
SG&A % of Revenue | 33.72% | 34.18% | 34.09% | 34.96% | 33.7% | 32.48% | 33.35% | 33.17% | 32.35% | - |
Research & Development | 2.19B | 2.26B | 2.33B | 2.33B | 2.49B | 2.75B | 2.7B | 2.73B | 2.73B | 2.89B |
R&D % of Revenue | 7.38% | 7.53% | 7.63% | 8.06% | 8.28% | 8.67% | 8.63% | 8.45% | 8.15% | - |
Other Operating Expenses | 2.82B | 1.75B | 2.39B | 2.26B | 2.51B | 2.75B | 1.91B | 2.53B | 2.37B | 1000K |
Operating Income | 5.38B▲ 0% | 6.64B▲ 23.4% | 6.27B▼ 5.6% | 4.79B▼ 23.6% | 4.48B▼ 6.4% | 5.75B▲ 28.3% | 5.49B▼ 4.6% | 5.14B▼ 6.2% | 5.96B▲ 15.8% | 6.34B▲ 0% |
Operating Margin % | 18.12% | 22.17% | 20.51% | 16.57% | 14.89% | 18.15% | 17.56% | 15.89% | 17.76% | 17.86% |
Operating Income Growth % | 0.41% | 23.35% | -5.6% | -23.56% | -6.41% | 28.28% | -4.64% | -6.22% | 15.77% | - |
EBITDA | 8.3B | 9.28B | 8.93B | 7.45B | 7.19B | 8.46B | 8.18B | 7.79B | 8.82B | 9.42B |
EBITDA Margin % | 27.94% | 31% | 29.21% | 25.78% | 23.86% | 26.7% | 26.2% | 24.07% | 26.29% | 26.55% |
EBITDA Growth % | 1.45% | 11.86% | -3.85% | -16.5% | -3.6% | 17.71% | -3.27% | -4.78% | 13.16% | 14.24% |
D&A (Non-Cash Add-back) | 2.92B | 2.64B | 2.66B | 2.66B | 2.7B | 2.71B | 2.7B | 2.65B | 2.86B | 3.08B |
EBIT | 5.7B | 6.82B | 6.64B | 5.15B | 4.82B | 6.07B | 6B | 5.56B | 6.36B | 6.27B |
Net Interest Income | -1.09B | -1.15B | -1.44B | -1.09B | -925M | -553M | -636M | -719M | -729M | -558M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 154M |
Interest Expense | 1.09B | 1.15B | 1.44B | 1.09B | 925M | 553M | 636M | 719M | 729M | 712M |
Other Income/Expense | -781M | -965M | -1.07B | -736M | -589M | -235M | -121M | -307M | -327M | -776M |
Pretax Income | 4.6B▲ 0% | 5.67B▲ 23.3% | 5.2B▼ 8.4% | 4.05B▼ 22.0% | 3.9B▼ 3.9% | 5.52B▲ 41.6% | 5.36B▼ 2.8% | 4.84B▼ 9.8% | 5.63B▲ 16.4% | 5.56B▲ 0% |
Pretax Margin % | 15.49% | 18.95% | 17.01% | 14.02% | 12.93% | 17.41% | 17.18% | 14.95% | 16.78% | 15.68% |
Income Tax | 578M | 2.58B | 547M | -751M | 265M | 456M | 1.58B | 1.13B | 936M | 923M |
Effective Tax Rate % | 12.56% | 45.46% | 10.53% | -18.52% | 6.8% | 8.27% | 29.46% | 23.42% | 16.63% | 16.59% |
Net Income | 4.03B▲ 0% | 3.1B▼ 22.9% | 4.63B▲ 49.2% | 4.79B▲ 3.4% | 3.61B▼ 24.7% | 5.04B▲ 39.7% | 3.76B▼ 25.4% | 3.68B▼ 2.2% | 4.66B▲ 26.8% | 4.61B▲ 0% |
Net Margin % | 13.56% | 10.36% | 15.16% | 16.56% | 11.97% | 15.9% | 12.03% | 11.36% | 13.9% | 13% |
Net Income Growth % | 13.85% | -22.94% | 49.19% | 3.41% | -24.7% | 39.74% | -25.42% | -2.18% | 26.82% | 8.31% |
Net Income (Continuing) | 4.02B | 3.1B | 4.65B | 4.81B | 3.63B | 5.06B | 3.78B | 3.7B | 4.69B | 4.64B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 122M | 102M | 121M | 135M | 174M | 171M | 182M | 206M | 232M | 211M |
EPS (Diluted) | 2.89▲ 0% | 2.27▼ 21.5% | 3.41▲ 50.2% | 3.54▲ 3.8% | 2.66▼ 24.9% | 3.73▲ 40.2% | 2.82▼ 24.4% | 2.76▼ 2.1% | 3.61▲ 30.8% | 3.58▲ 0% |
EPS Growth % | 16.53% | -21.45% | 50.22% | 3.81% | -24.86% | 40.23% | -24.4% | -2.13% | 30.8% | 9.12% |
EPS (Basic) | 2.92 | 2.29 | 3.44 | 3.57 | 2.68 | 3.75 | 2.83 | 2.77 | 3.63 | - |
Diluted Shares Outstanding | 1.39B | 1.37B | 1.36B | 1.35B | 1.35B | 1.35B | 1.33B | 1.33B | 1.29B | 1.29B |
Basic Shares Outstanding | 1.38B | 1.36B | 1.35B | 1.34B | 1.34B | 1.34B | 1.33B | 1.33B | 1.29B | 1.28B |
Dividend Payout Ratio | 58.99% | 80.35% | 58.15% | 60.43% | 86.52% | 67.14% | 96.22% | 99.73% | 76.98% | - |
MDT Balance Sheet
Medtronic plc (MDT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 24.87B | 22.98B | 21.97B | 22.03B | 22.55B | 23.06B | 21.68B | 21.93B | 23.81B | 24.07B |
Cash & Short-Term Investments | 13.71B | 11.23B | 9.85B | 10.95B | 10.82B | 10.57B | 7.96B | 8.01B | 8.96B | 8.38B |
Cash Only | 4.97B | 3.67B | 4.39B | 4.14B | 3.59B | 3.71B | 1.54B | 1.28B | 2.22B | 1.15B |
Short-Term Investments | 8.74B | 7.56B | 5.46B | 6.81B | 7.22B | 6.86B | 6.42B | 6.72B | 6.75B | 7.24B |
Accounts Receivable | 5.59B | 5.99B | 6.22B | 4.64B | 5.46B | 5.55B | 6B | 6.13B | 6.51B | 87M |
Days Sales Outstanding | 68.69 | 72.96 | 74.32 | 58.64 | 66.2 | 63.94 | 70.11 | 69.11 | 70.91 | 49.51 |
Inventory | 3.34B | 3.58B | 3.75B | 4.23B | 4.31B | 4.62B | 5.29B | 5.22B | 5.48B | -803M |
Days Inventory Outstanding | 131.09 | 144.08 | 149.63 | 163.79 | 150.17 | 166.08 | 180.24 | 169.78 | 171.83 | 70.67 |
Other Current Assets | 2.24B | 2.19B | 2.14B | 2.21B | 1.96B | 2.32B | 2.42B | 2.58B | 2.86B | 16.4B |
Total Non-Current Assets | 74.98B | 68.41B | 67.73B | 68.66B | 70.53B | 67.92B | 69.27B | 68.05B | 67.86B | 67.41B |
Property, Plant & Equipment | 4.36B | 4.6B | 4.67B | 4.83B | 5.22B | 5.41B | 5.57B | 6.13B | 6.84B | -1.42B |
Fixed Asset Turnover | 6.81x | 6.51x | 6.54x | 5.99x | 5.77x | 5.85x | 5.61x | 5.28x | 4.91x | 11.75x |
Goodwill | 38.52B | 39.54B | 39.96B | 39.84B | 41.96B | 40.5B | 41.42B | 40.99B | 41.74B | 41.89B |
Intangible Assets | 23.41B | 21.72B | 20.56B | 19.06B | 17.74B | 15.59B | 14.84B | 13.22B | 11.67B | 10.34B |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.38B |
Other Non-Current Assets | 8.7B | 2.54B | 2.53B | 4.93B | 5.61B | 6.41B | 7.44B | 7.7B | 7.62B | 15.22B |
Total Assets | 99.82B▲ 0% | 91.39B▼ 8.4% | 89.69B▼ 1.9% | 90.69B▲ 1.1% | 93.08B▲ 2.6% | 90.98B▼ 2.3% | 90.95B▼ 0.0% | 89.98B▼ 1.1% | 91.68B▲ 1.9% | 91.48B▲ 0% |
Asset Turnover | 0.30x | 0.33x | 0.34x | 0.32x | 0.32x | 0.35x | 0.34x | 0.36x | 0.37x | 0.39x |
Asset Growth % | 0.27% | -8.44% | -1.86% | 1.11% | 2.64% | -2.26% | -0.04% | -1.06% | 1.89% | 6.38% |
Total Current Liabilities | 14.26B | 10.08B | 8.47B | 10.37B | 8.51B | 12.39B | 9.05B | 10.79B | 12.88B | 9.49B |
Accounts Payable | 1.55B | 1.63B | 1.95B | 2B | 2.11B | 2.28B | 2.66B | 2.41B | 2.45B | 2.57B |
Days Payables Outstanding | 61.07 | 65.54 | 77.86 | 77.31 | 73.33 | 81.89 | 90.65 | 78.43 | 76.85 | 68.63 |
Short-Term Debt | 7.52B | 2.06B | 832M | 2.77B | 2M | 3.74B | 13M | 1.09B | 2.87B | 191M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.94B | 1.99B | 2.19B | 2.1B | 2.48B | 2.12B | 1.95B | 2.38B | 2.52B | 6.08B |
Current Ratio | 1.74x | 2.28x | 2.59x | 2.13x | 2.65x | 1.86x | 2.39x | 2.03x | 1.85x | 2.54x |
Quick Ratio | 1.51x | 1.92x | 2.15x | 1.72x | 2.14x | 1.49x | 1.81x | 1.55x | 1.42x | 2.62x |
Cash Conversion Cycle | 138.71 | 151.5 | 146.09 | 145.12 | 143.04 | 148.13 | 159.7 | 160.46 | 165.89 | 51.55 |
Total Non-Current Liabilities | 35.18B | 30.49B | 31.01B | 29.45B | 32.97B | 25.86B | 30.23B | 28.77B | 30.55B | 32.79B |
Long-Term Debt | 25.86B | 23.68B | 24.47B | 21.98B | 26.32B | 20.32B | 24.29B | 23.88B | 25.59B | 27.88B |
Capital Lease Obligations | 23M | 21M | 10M | 45M | 62M | 56M | 57M | 55M | 52M | 216M |
Deferred Tax Liabilities | 2.98B | 1.42B | 1.28B | 1.17B | 1.03B | 884M | 708M | 515M | 403M | 1.57B |
Other Non-Current Liabilities | 6.4B | 5.36B | 5.25B | 6.26B | 5.57B | 4.61B | 5.18B | 4.33B | 4.5B | 4.45B |
Total Liabilities | 49.4B | 40.57B | 39.48B | 39.82B | 41.48B | 38.26B | 39.28B | 39.56B | 43.42B | 42.29B |
Total Debt | 33.4B | 25.76B | 25.32B | 24.8B | 26.39B | 24.11B | 24.36B | 25.02B | 28.52B | 28.07B |
Net Debt | 28.43B | 22.09B | 20.92B | 20.66B | 22.8B | 20.4B | 22.82B | 23.74B | 26.3B | 26.92B |
Debt / Equity | 0.66x | 0.51x | 0.50x | 0.49x | 0.51x | 0.46x | 0.47x | 0.50x | 0.59x | 0.57x |
Debt / EBITDA | 4.02x | 2.77x | 2.84x | 3.33x | 3.67x | 2.85x | 2.98x | 3.21x | 3.23x | 2.98x |
Net Debt / EBITDA | 3.43x | 2.38x | 2.34x | 2.77x | 3.17x | 2.41x | 2.79x | 3.05x | 2.98x | 2.86x |
Interest Coverage | 5.21x | 5.95x | 4.60x | 4.71x | 5.21x | 10.98x | 9.43x | 7.73x | 8.72x | 8.81x |
Total Equity | 50.42B▲ 0% | 50.82B▲ 0.8% | 50.21B▼ 1.2% | 50.87B▲ 1.3% | 51.6B▲ 1.4% | 52.72B▲ 2.2% | 51.66B▼ 2.0% | 50.42B▼ 2.4% | 48.26B▼ 4.3% | 49.2B▲ 0% |
Equity Growth % | -2.72% | 0.81% | -1.2% | 1.31% | 1.44% | 2.17% | -2% | -2.41% | -4.29% | -4.9% |
Book Value per Share | 36.23 | 37.15 | 36.99 | 37.65 | 38.11 | 39.01 | 38.76 | 37.90 | 37.41 | 38.19 |
Total Shareholders' Equity | 50.29B | 50.72B | 50.09B | 50.74B | 51.43B | 52.55B | 51.48B | 50.21B | 48.02B | 48.98B |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -181M |
Retained Earnings | 23.36B | 24.38B | 26.27B | 28.13B | 28.59B | 30.25B | 30.39B | 30.4B | 31.48B | 32.3B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.61B | -1.79B | -2.71B | -3.56B | -3.48B | -2.27B | -3.5B | -3.32B | -4.28B | -4.33B |
Minority Interest | 122M | 102M | 121M | 135M | 174M | 171M | 182M | 206M | 232M | 211M |
MDT Cash Flow Statement
Medtronic plc (MDT) cash flow — operating, investing & free cash flow history
| Metric | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 6.88B | 4.68B | 7.01B | 7.23B | 6.24B | 7.35B | 6.04B | 6.79B | 7.04B | 7.29B |
Operating CF Margin % | 23.16% | 15.64% | 22.93% | 25.02% | 20.72% | 23.18% | 19.34% | 20.97% | 21% | - |
Operating CF Growth % | 31.85% | -31.92% | 49.59% | 3.24% | -13.74% | 17.72% | -17.79% | 12.39% | 3.79% | 4.62% |
Net Income | 4.02B | 3.1B | 4.65B | 4.81B | 3.63B | 5.06B | 3.78B | 3.68B | 4.69B | 4.61B |
Depreciation & Amortization | 2.92B | 2.64B | 2.66B | 2.66B | 2.7B | 2.71B | 2.7B | 2.65B | 2.86B | 3.17B |
Stock-Based Compensation | 348M | 344M | 290M | 297M | 344M | 359M | 355M | 393M | 429M | 451M |
Deferred Taxes | -459M | -919M | -304M | -1.31B | -422M | -604M | -226M | -508M | -316M | -176M |
Other Non-Cash Items | -89M | -307M | 792M | 722M | 687M | 711M | 396M | 1.06B | 433M | 633M |
Working Capital Changes | 139M | -173M | -1.08B | 61M | -701M | -889M | -967M | -484M | -1.05B | -1.42B |
Change in Receivables | -75M | -275M | -581M | 1.29B | -761M | -477M | -576M | -391M | -433M | -162M |
Change in Inventory | -227M | -192M | -274M | -577M | 78M | -560M | -939M | -139M | -292M | -617M |
Change in Payables | 356M | 65M | 399M | -44M | 531M | 213M | 696M | 391M | 209M | 289M |
Cash from Investing | -1.57B | 5.86B | -774M | -3.2B | -2.87B | -1.66B | -3.49B | -2.37B | -1.94B | -2.51B |
Capital Expenditures | -1.25B | -1.07B | -1.13B | -1.21B | -1.35B | -1.37B | -1.46B | -1.59B | -1.86B | -1.88B |
CapEx % of Revenue | 4.22% | 3.57% | 3.71% | 4.2% | 4.5% | 4.32% | 4.67% | 4.9% | 5.54% | 5.28% |
Acquisitions | -1.32B | 5.92B | -1.83B | -488M | -994M | -91M | -1.87B | -211M | -98M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 22M | -22M | 36M | -37M | -54M | -10M | 4M | -261M | -249M | -149M |
Cash from Financing | -3.28B | -11.95B | -5.43B | -4.2B | -4.14B | -5.34B | -4.96B | -4.45B | -4.36B | -5.21B |
Debt Issued (Net) | 2.18B | -7.6B | -867M | -559M | -570M | -1M | -598M | 1.07B | 2.14B | -1.01B |
Equity Issued (Net) | -3.12B | -1.77B | -1.89B | -1.33B | -652M | -2.12B | -645M | -1.85B | -2.73B | -347M |
Dividends Paid | -2.38B | -2.49B | -2.69B | -2.89B | -3.12B | -3.38B | -3.62B | -3.67B | -3.59B | -3.63B |
Share Repurchases | -3.54B | -2.17B | -2.88B | -1.33B | -652M | -2.54B | -645M | -2.14B | -3.23B | -874M |
Other Financing | 26M | -94M | 14M | 581M | 206M | 163M | -101M | -3M | -184M | -221M |
Net Change in Cash | 2.09B▲ 0% | -1.3B▼ 162.1% | 724M▲ 155.8% | -253M▼ 134.9% | -547M▼ 116.2% | 121M▲ 122.1% | -2.17B▼ 1894.2% | -259M▲ 88.1% | 934M▲ 460.6% | -2.65B▲ 0% |
Free Cash Flow | 5.63B▲ 0% | 3.62B▼ 35.7% | 5.87B▲ 62.4% | 6.02B▲ 2.5% | 4.88B▼ 18.9% | 5.98B▲ 22.4% | 4.58B▼ 23.4% | 5.2B▲ 13.5% | 5.18B▼ 0.3% | 5.41B▲ 0% |
FCF Margin % | 18.94% | 12.07% | 19.22% | 20.82% | 16.22% | 18.87% | 14.67% | 16.07% | 15.46% | 15.25% |
FCF Growth % | 34.85% | -35.73% | 62.42% | 2.52% | -18.87% | 22.37% | -23.39% | 13.54% | -0.29% | -1.04% |
FCF per Share | 4.04 | 2.64 | 4.33 | 4.46 | 3.61 | 4.42 | 3.44 | 3.91 | 4.02 | 4.20 |
FCF Conversion (FCF/Net Income) | 1.71x | 1.51x | 1.51x | 1.51x | 1.73x | 1.46x | 1.61x | 1.85x | 1.51x | 1.17x |
Interest Paid | 1.13B | 1.15B | 973M | 643M | 582M | 540M | 606M | 826M | 762M | 768M |
Taxes Paid | 1.03B | 2.54B | 1.56B | 878M | 1.25B | 996M | 1.55B | 1.62B | 1.82B | -121M |
MDT Key Ratios
Medtronic plc (MDT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 7.88% | 6.13% | 9.17% | 9.48% | 7.04% | 9.66% | 7.2% | 7.2% | 9.45% | 9.49% |
Return on Invested Capital (ROIC) | 5.08% | 6.56% | 6.53% | 5.04% | 4.61% | 5.85% | 5.57% | 5.19% | 6.01% | 6.28% |
Gross Margin | 68.72% | 69.73% | 70.04% | 67.41% | 65.19% | 67.98% | 65.67% | 65.34% | 65.32% | 61.95% |
Net Margin | 13.56% | 10.36% | 15.16% | 16.56% | 11.97% | 15.9% | 12.03% | 11.36% | 13.9% | 13% |
Debt / Equity | 0.66x | 0.51x | 0.50x | 0.49x | 0.51x | 0.46x | 0.47x | 0.50x | 0.59x | 0.57x |
Interest Coverage | 5.21x | 5.95x | 4.60x | 4.71x | 5.21x | 10.98x | 9.43x | 7.73x | 8.72x | 8.81x |
FCF Conversion | 1.71x | 1.51x | 1.51x | 1.51x | 1.73x | 1.46x | 1.61x | 1.85x | 1.51x | 1.17x |
Revenue Growth | 3.04% | 0.82% | 2.02% | -5.38% | 4.16% | 5.21% | -1.45% | 3.64% | 3.62% | 6.88% |
Related:MDT Dividend History·MDT Revenue History·MDT Price History·MDT P/E History·MDT Financial Ratios·MDT Institutional Holders
MDT SEC Filings & Documents
Medtronic plc (MDT) SEC filings — annual & quarterly reports (10-K, 10-Q)
MDT Frequently Asked Questions
Medtronic plc (MDT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Medtronic plc (MDT) reported $35.48B in revenue for fiscal year 2025. This represents a 1536% increase from $2.17B in 1996.
Medtronic plc (MDT) grew revenue by 3.6% over the past year. Growth has been modest.
Yes, Medtronic plc (MDT) is profitable, generating $4.61B in net income for fiscal year 2025 (13.9% net margin).
Dividend & Returns
Yes, Medtronic plc (MDT) pays a dividend with a yield of 3.51%. This makes it attractive for income-focused investors.
Medtronic plc (MDT) has a return on equity (ROE) of 9.4%. This is below average, suggesting room for improvement.
Medtronic plc (MDT) generated $5.41B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.